menu
    • menu
    [{"orgOrder":0,"company":"Ra Pharmaceuticals","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Acquisition","leadProduct":"Zilucoplan Sodium","moa":"C5 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Ra Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ra Pharmaceuticals \/ UCB Pharma S.A","highestDevelopmentStatusID":"10","companyTruncated":"Ra Pharmaceuticals \/ UCB Pharma S.A"},{"orgOrder":0,"company":"Ra Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"C5 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Ra Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ra Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ra Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ra Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Zilucoplan Sodium","moa":"C5 receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Ra Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ra Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Ra Pharmaceuticals \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Ra Pharmaceuticals

    Menu

    Ra Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Ra Pharmaceuticals

                            U.S.A arrow
                            Peptide-Based Therapeutics Summit
                            Not Confirmed

                            Ra Pharmaceuticals

                            U.S.A arrow
                            Peptide-Based Therapeutics Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zilucoplan Sodium

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ra Pharmaceuticals Announces Publication of Zilucoplan Phase 2 gMG Trial Results in JAMA Neurology

                            Details : the study demonstrated that zilucoplan resulted in rapid, clinically meaningful, statistically significant, and sustained improvements in the primary and key secondary endpoints.

                            Product Name : RA101495

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            February 18, 2020

                            Lead Product(s) : Zilucoplan Sodium

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Ra Pharmaceuticals

                            U.S.A arrow
                            Peptide-Based Therapeutics Summit
                            Not Confirmed

                            Ra Pharmaceuticals

                            U.S.A arrow
                            Peptide-Based Therapeutics Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zilucoplan Sodium

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : UCB Pharma S.A

                            Deal Size : $2,300.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            UCB Completes the Acquisition of Ra Pharmaceuticals - to Deliver Differentiated Therapies to Patients

                            Details : The transaction will enhance UCB’s potential to be a leader in myasthenia gravis by adding zilucoplan, currently in phase 3, to the UCB pipeline alongside rozanolixizumab.

                            Product Name : RA101495

                            Product Type : Peptide

                            Upfront Cash : Undisclosed

                            February 04, 2020

                            Lead Product(s) : Zilucoplan Sodium

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : UCB Pharma S.A

                            Deal Size : $2,300.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Ra Pharmaceuticals

                            U.S.A arrow
                            Peptide-Based Therapeutics Summit
                            Not Confirmed

                            Ra Pharmaceuticals

                            U.S.A arrow
                            Peptide-Based Therapeutics Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zilucoplan Sodium

                            Therapeutic Area : Neurology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ra Pharmaceuticals Announces Clearance of IND Application for the HEALEY ALS Platform Trial

                            Details : Zilucoplan was selected as one of the first clinical candidates to be evaluated in this platform trial for ALS led by the Sean M. Healey & AMG Center for ALS at Mass General.

                            Product Name : RA101495

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            January 22, 2020

                            Lead Product(s) : Zilucoplan Sodium

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth